Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in T2D patients on insulin pump
NCT01140893Phase 3Unknown
- Sponsor
- CHU Caen Normandie
- Start
- Nov 2010
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 6 months. Status: unknown.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01140893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140893.